natgillin/translations-raw huggingface dataset:
The efficacy of some hormonal contraceptives may be reduced if co-administered with olaparib (see sections 4.4 and 4.6). 
Učinkovitost nekaterih hormonskih kontraceptivov se lahko zmanjša, če so uporabljeni sočasno z olaparibom (glejte poglavji 4.4 in 4.6).
The duration of therapy with olaparib in patients who developed MDS/AML varied from < 6 months to > 2 years. 
Pri bolnicah, ki so zbolele za MDS/AML, je zdravljenje z olaparibom trajalo od < 6 mesecev do > 2 leti.
In this study 391 patients were randomised 2:1 to receive either Lynparza (300 mg [2 x 150 mg tablets] twice daily) or placebo. 
V tej študiji so 391 bolnic v razmerju 2:1 randomizirali bodisi na prejemanje zdravila Lynparza (300 mg [2 x 150 mg v tabletah] dvakrat na dan) bodisi na prejemanje placeba.
Table 8 
Slika 8.
Response to prior platinum chemotherapy was complete in 47% and partial in 53% of the patients. 
Odziv na predhodno kemoterapijo na osnovi platine je bil popoln pri 47 % bolnic in delen pri 53 % bolnic.
Patients should start treatment with Lynparza no later than 8 weeks after completion of their final dose of the platinum-containing regimen. 
Bolnice morajo začeti zdravljenje z zdravilom Lynparza najpozneje v 8 tednih po zadnjem odmerku sheme zdravljenja na osnovi platine.
Therefore, caution should be exercised when sensitive CYP3A substrates or substrates with a narrow therapeutic margin (e.g. simvastatin, cisapride, cyclosporine, ergot alkaloids, fentanyl, pimozide, sirolimus, tacrolimus and quetiapine) are combined with olaparib. 
Zato je potrebna previdnost pri sočasni uporabi olapariba z občutljivimi substrati CYP3A4 ali substrati, ki imajo ozko terapevtsko okno (npr. s simvastatinom, cisapridom, ciklosporinom, ergot alkaloidi, fentanilom, pimozidom, sirolimusom, takrolimusom in kvetiapinom).
The analysis was performed using a Cox proportional hazard model including response to previous platinum chemotherapy (CR or PR), and time to disease progression (>6-12 months and >12 months) in the penultimate platinum-based chemotherapy as covariates. 
Analiza je bila narejena s Coxovim modelom sorazmernih ogroženosti, ki je kot sospremenljivko vključeval odziv na predhodno kemoterapijo na osnovi platine (CR ali PR) in časom do napredovanja bolezni (> 6-12 mesecev ali več kot 12 mesecev) med predzadnjo kemoterapijo na osnovi platine.
Treatment may be interrupted to manage adverse reactions such as nausea, vomiting, diarrhoea, and anaemia and dose reduction can be considered (see section 4.8). 
Zdravljenje je mogoče prekiniti za obvladanje neželenih učinkov, kot so navzea, bruhanje, driska ali anemija; v poštev pride zmanjšanje odmerka (glejte poglavje 4.8).
There were 389 patients who were germline BRCA1/2m and 2 who were somatic BRCA1/2m in SOLO1. 
V študiji SOLO1 je bilo 389 bolnic z germinalno BRCA1/2m in 2 s somatsko BRCA1/2m.
P value (2-sided) 
Vrednost p (2-stranska)
A clinical study to evaluate the impact of rifampicin, a known CYP3A inducer, has shown that co-administration with olaparib decreased olaparib mean Cmax by 71% (90% CI: 76-67%) and mean AUC by 87% (90% CI: 89-84%). 
Klinična študija za oceno vpliva rifampicina, ki je znan induktor CYP3A, je pokazala, da je njegova sočasna uporaba z olaparibom zmanjšala srednjo vrednost Cmax olapariba za 71 % (90 % IZ: 76 do 67 %) in srednjo vrednost AUC olapariba za 87 % (90 % IZ: 89 do 84 %).
If pneumonitis is confirmed, Lynparza treatment should be discontinued and the patient treated appropriately. 
Če je pnevmonitis potrjen, je treba zdravljenje z zdravilom Lynparza prekiniti in bolnika ustrezno zdraviti.
Capsule content Lauroyl macrogol-32 glycerides 
Vsebina kapsule makrogolglicerol lavrat-32
Vomiting was reported early, with first onset within the first two months of Lynparza treatment in the majority of patients. 
O bruhanju so poročali zgodaj in se je pri večini bolnic prvič pojavilo v prvih dveh mesecih zdravljenja z zdravilom Lynparza.
Patients with PR at study entry either achieved CR (15% in olaparib arm and 4% in the placebo arm at 24 months, remained in CR at 36 months) or had further PR/stable disease (43% in olaparib arm and 15% in the placebo arm at 24 months; 17% in olaparib arm and 15% in placebo arm at 36 months). 
Bolnice z delnim odzivom (PR) ob vstopu v študijo so bodisi dosegle popoln odziv (CR) (15 % v skupini z olaparibom in 4 % v skupini s placebom po 24 mesecih; so ostale v popolnem odzivu (CR) po 36 mesecih) bodisi so bile še naprej v delnem odzivu (PR)/imele stabilno bolezen (43 % v skupini z olaparibom in 15 % v skupini s placebom po 24 mesecih; 17 % v skupini z olaparibom in 15 % v skupini s placebom po 36 mesecih).
If you take more Lynparza than your normal dose, contact your doctor or nearest hospital straight away. 
Če ste vzeli večji odmerek zdravila Lynparza, kot bi smeli Če vzamete odmerek zdravila Lynparza, ki je večji od vašega normalnega odmerka, se takoj posvetujte z zdravnikom ali pojdite v najbližjo bolnišnico.
The pharmacokinetics of olaparib at the 400 mg twice daily capsule dose are characterised by an apparent plasma clearance of ~8.6 L/h, an apparent volume of distribution of ~167 L and a terminal half-life of 11.9 hours. 
Farmakokinetika med uporabo olapariba v kapsulah 400 mg dvakrat na dan kaže navidezni plazemski očistek ~8,6 L/uro, navidezni volumen porazdelitve ~167 L in končni razpolovni čas 11,9 ure.
PFS (77% maturity) - DCO 09 December 2016 
PFS (77 % zrelost) - DCO 09. december 2016
Film-coated tablets Multipack: 112 (2 packs of 56) film-coated tablets 
filmsko obložene tablete skupno pakiranje: 112 (2 pakiranji po 56) filmsko obloženih tablet
The most frequent adverse reactions leading to dose interruption or dose reduction were anaemia, nausea and vomiting. 
Najpogostejši neželeni učinki, ki so povzročili prekinitev uporabe ali zmanjšanje odmerka, so bili anemija, navzea in bruhanje.
• fentanyl - used to treat cancer pain 
• fentanil - uporablja se za zdravljenje bolečin zaradi raka,
• herbal remedies containing St John's Wort (Hypericum perforatum) - used mainly for depression 
• zeliščna zdravila, ki vsebujejo šentjanževko (Hypericum perforatum) - v glavnem se uporablja za zdravljenje depresije,
Median age was 53 years in both arms. 
Mediana starost je bila v obeh skupinah 53 let.
The most frequently observed adverse reactions across clinical trials in patients receiving Lynparza monotherapy (≥ 10%) were nausea, vomiting, diarrhoea, dyspepsia, fatigue, headache, dysgeusia, decreased appetite, dizziness, upper abdominal pain, cough, dyspnoea, anaemia, neutropenia, thrombocytopenia and leukopenia. 
V kliničnih preizkušanjih so pri monoterapiji z zdravilom Lynparza najpogosteje (≥ 10 %) opažali naslednje neželene učinke: navzeo, bruhanje, drisko, dispepsijo, utrujenost, glavobol, motnje okušanja, zmanjšanje apetita, omotico, bolečine v zgornjem delu trebuha, kašelj, dispnejo, anemijo, nevtropenijo, trombocitopenijo in levkopenijo.
Adverse reactions that most commonly led to permanent discontinuation were anaemia (1.3%), nausea (0.8%) and thrombocytopenia (0.5%). 
Neželeni učinki, ki so najpogosteje povzročili trajno prenehanje uporabe, so bili anemija (1,3 %), navzea (0,8 %) in trombocitopenija (0,5 %).
In patients with mild hepatic impairment (Child-Pugh classification A), AUC increased by 15% and Cmax by 13% and in patients with moderate hepatic impairment (Child-Pugh classification B), AUC increased by 8% and Cmax decreased by 13% compared with patients with normal hepatic function. 
Pri bolnicah z blago okvaro jeter (klasifikacija Child-Pugh A) se je vrednost AUC povečala za 15 % in vrednost Cmax za 13 %, pri bolnicah z zmerno okvaro jeter (klasifikacija Child-Pugh B) pa se je vrednost AUC povečala za 8 % medtem ko se je vrednost Cmax zmanjšala za 13 % v primerjavi z bolnicami z normalnim delovanjem jeter.
Following oral administration of olaparib via the tablet formulation (2 x 150 mg), absorption is rapid with median peak plasma concentrations typically achieved 1.5 hours after dosing. 
Po peroralni uporabi olapariba v obliki tablet (dvakrat 150 mg) je absorpcija hitra in mediana največja koncentracija v plazmi je praviloma dosežena 1,5 ur po uporabi.
Male patients must use a condom during therapy and for 3 months after receiving the last dose of Lynparza when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. 
Moški bolniki morajo med zdravljenjem in še 3 mesece po prejetju zadnjega odmerka zdravila Lynparza med spolnimi odnosi z nosečo žensko ali žensko v rodni dobi uporabljati kondom.
Therefore, caution should be taken if these medicinal products are co-administered with Lynparza and patients should be closely monitored. 
Zato je v primeru sočasne uporabe teh zdravil in zdravila Lynparza potrebna previdnost, bolnike pa je potrebno skrbno spremljati.
If you think any of these may apply to you, talk to your doctor, pharmacist or nurse before or during treatment with Lynparza. 
Če menite, da kaj od tega velja za vas, se pred začetkom zdravljenja z zdravilom Lynparza ali med zdravljenjem z njim posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
In first-line ovarian cancer maintenance treatment, patients experienced nausea events (77% on olaparib, 38% on placebo), vomiting (40% on olaparib, 15% on placebo), diarrhoea (34% on olaparib, 25% on placebo) and dyspepsia (17% on olaparib, 12% on placebo). 
Med vzdrževalnim zdravljenjem prve linije raka jajčnikov so se bolnicam pojavili navzea (77 % pri olaparibu, 38 % pri placebu), bruhanje (40 % pri olaparibu, 15 % pri placebu), driska (34 % pri olaparibu, 25 % pri placebu) in dispepsija (17 % pri olaparibu, 12 % pri placebu).
A ring-opened piperazin-3-ol moiety, and two mono-oxygenated metabolites (each ~10%) were the major circulating components, with one of the mono-oxygenated metabolites also being the major metabolite in the excreta (6% and 5% of the urinary and faecal radioactivity, respectively). 
Glavne snovi v obtoku so bile piperazin-3-ol skupina z razklenjenim obročem in dva monooksigenirana presnovka (vsak ~10 %); eden od obeh monooksigeniranih presnovkov je bil tudi glavni izločeni presnovek (6 % radioaktivnosti v urinu in 5 % radioaktivnosti v blatu).
PR, defined as the presence of any measurable or non-measurable lesions at baseline or elevated CA-125, was reported in 27% and 23% of patients in the olaparib and placebo arms, respectively. 
Delni odziv (PR), opredeljen kot prisotnost kakršne koli merljive ali nemerljive lezije izhodiščno ali zvišana raven CA-125, je imelo 27 % bolnic v skupini z olaparibom in 23 % bolnic v skupini s placebom.
Anaemia was the most common CTCAE grade ≥3 adverse reaction reported in clinical studies. 
Anemija je bila v kliničnih študijah najpogosteje zabeleženi neželeni učinek ≥ 3. stopnje po CTCAE.
In population based PK analyses, patient age, bodyweight or race (including White and Japanese patients) were not significant covariates. 
V populacijski farmakokinetični analizi starost bolnice, telesna masa ali rasa (vključno z belkami in japonskimi bolnicami) niso bile pomembne sospremenljivke.
Nausea events led to discontinuation in 2.3% of olaparib-treated patients (CTCAE Grade 2) and 0.8% of placebo-treated patients (CTCAE Grade 1); 0.8% and 0.4% of olaparib-treated patients discontinued treatment due to low grade (CTCAE Grade 2) vomiting and dyspepsia, respectively. 
Primeri navzee so vodili do prenehanja zdravljenja pri 2,3 % bolnic, zdravljenih z olaparibom (2. stopnja po CTCAE), in pri 0,8 % bolnic, ki so prejemale placebo (1. stopnja po CTCAE); od bolnic, zdravljenih z olaparibom, je zaradi bruhanja oz. dispepsije nizke stopnje (2. stopnja po CTCAE) zdravljenje prenehalo 0,8 % bolnic oz. 0,4 % bolnic.
In this study 302 patients with a documented deleterious or suspected deleterious gBRCA mutation were randomised 2:1 to receive either Lynparza (300 mg [2 x 150 mg tablets] twice daily) or physician's choice of chemotherapy (capecitabine 42%, eribulin 35%, or vinorelbine 17%) until progression or unacceptable toxicity. 
V tej študiji so 302 bolnika s potrjeno škodljivo ali domnevno škodljivo mutacijo gBRCA v razmerju 2:1 randomizirali na prejemanje bodisi zdravila Lynparza (300 mg [2 x 150 mg v tabletah] dvakrat na dan) bodisi na kemoterapijo po zdravnikovi izbiri (42 % kapecitabin, 35 % eribulin ali 17 % vinorelbin), in sicer do napredovanja bolezni ali nesprejemljive toksičnosti.
If patients present with new or worsening respiratory symptoms such as dyspnoea, cough and fever, or an abnormal chest radiologic finding is observed, Lynparza treatment should be interrupted and prompt investigation initiated. 
Če se pri bolniku pojavijo novi ali poslabšajo obstoječi dihalni simptomi, npr. dispneja, kašelj in zvišana telesna temperatura, ali je ugotovljen nenormalen radiološki izvid prsnih organov, je treba zdravljenje z zdravilom Lynparza prekiniti in takoj opraviti preiskave.
The safety and efficacy of olaparib in patients with gBRCA1/2-mutations who had HER2-negative metastatic breast cancer were studied in a Phase III randomised, open-label, controlled trial (OlympiAD). 
Varnost in učinkovitost olapariba pri bolnikih z mutacijami gBRCA1/2 in HER2-negativnim metastatskim rakom dojk so raziskali v randomiziranem, odprtem kontroliranem preskušanju III. faze (OlympiAD).
Ovarian cancer was the primary tumour in 86% of the patients. 
Rak jajčnikov je bil primarni tumor pri 86 % bolnic.
• cyclosporine, sirolimus, tacrolimus - used to suppress the immune system 
• ciklosporin, sirolimus, takrolimus - uporabljajo se za zaviranje imunskega sistema,
• Your doctor will tell you how many capsules of Lynparza to take. 
• Zdravnik vam bo povedal, koliko kapsul zdravila Lynparza morate vzeti.
Iron oxide black (E172) 
Črnilo šelak črni železov oksid (E172)
Adverse reactions that most commonly led to dose interruptions and/ or reductions were anaemia (13.9%), vomiting (7.1%), nausea (6.6%), fatigue/asthenia (6.1%) and neutropenia (5.8%). 
Neželeni učinki, ki so najpogosteje povzročili prekinitev uporabe in/ali zmanjšanje odmerka, so bili anemija (13,9 %), bruhanje (7,1 %), navzea (6,6 %), utrujenost/astenija (6,1 %) in nevtropenija (5,8 %).
Patients could not have received prior olaparib or other PARP inhibitor treatment. 
Bolnice predhodno niso smele dobivati olapariba ali drugih zaviralcev PARP.
Number of patients at risk Olaparib 300 mg twice daily tablet 
Število izpostavljenih tveganju Olaparib 300 mg tableta dvakrat na dan
There are no data in patients with severe hepatic impairment (Child-Pugh classification C). 
Podatkov pri bolnikih s hudo okvaro jeter ni (klasifikacija Child-Pugh C).
In vitro, olaparib has been shown to be an inhibitor of BCRP, OATP1B1, OCT1, OCT2, OAT3, MATE1 and MATE2K. 
In vitro je ugotovljeno, da olaparib zavira BCRP, OATP1B1, OCT1, OCT2, OAT3, MATE1 in MATE2K.
Very common Decreased appetite 
Presnovne in prehranske motnje zelo pogosti zmanjšanje apetita občasni zmanjšanje apetita
Secondary efficacy endpoints included time from randomisation to second progression or death (PFS2), overall survival (OS), time from randomisation to discontinuation of treatment or death (TDT), time from randomisation to first subsequent anticancer therapy or death (TFST) and health related quality of life (HRQoL). 
Sekundarni opazovani dogodki učinkovitosti so obsegali čas od randomizacije do drugega napredovanja bolezni ali smrti (PFS2), celokupno preživetje (OS), čas od randomizacije do prenehanja zdravljenja ali smrti (TDT - time to discontinuation of treatment), čas od randomizacije do prvega nadaljnjega zdravljenja proti raku ali smrti (TFST - time to first subsequent therapy) in zdravstveno kakovost življenja (HRQoL - health related quality of life).
Therefore, known strong inducers of this isozyme (e.g. phenytoin, rifampicin, rifapentine, carbamazepine, nevirapine, phenobarbital and St John's Wort) are not recommended with Lynparza, as it is possible that the efficacy of Lynparza could be substantially reduced. 
Zato zdravila Lynparza ni priporočljivo uporabljati z znanimi močnimi induktorji tega izoencima (npr. s fenitoinom, rifampicinom, rifapentinom, karbamazepinom, nevirapinom, fenobarbitalom in šentjanževko), ker obstaja možnost, da se učinkovitost zdravila Lynparza bistveno zmanjša.
Film-coated tablets 56 film-coated tablets 
filmsko obložene tablete 56 filmsko obloženih tablet
If a patient develops severe haematological toxicity or blood transfusion dependence, treatment with Lynparza should be interrupted and appropriate haematological testing should be initiated. 
Če se pri bolniku pojavijo hudi hematotoksični učinki ali je odvisen od transfuzij krvi, je treba zdravljenje z zdravilom Lynparza prekiniti in uvesti ustrezno hematološko testiranje.
• Tablet core: copovidone, silica colloidal anhydrous, mannitol, sodium stearyl fumarate. 
• Jedro tablete: kopovidon, koloidni brezvodni silicijev dioksid, manitol, natrijev stearilfumarat.
The recommended dose of Lynparza is 400 mg (eight capsules) taken twice daily, equivalent to a total daily dose of 800 mg. 
Priporočeni odmerek zdravila Lynparza je 400 mg (osem kapsul) dvakrat na dan; to ustreza celotnemu dnevnemu odmerku 800 mg.
Summary of key efficacy findings for patients with gBRCA1/2-mutated HER2negative metastatic breast cancer in OlympiAD 
Povzetek ključnih izsledkov o učinkovitosti pri bolnikih s HER2-negativnim metastatskim rakom dojk z mutacijo gBRCA1/2 v OlympiAD
• Tablet coating: hypromellose, macrogol 400, titanium dioxide (E171), iron oxide yellow 
• Obloga tablete: hipromeloza, makrogol 400, titanov dioksid (E171), rumeni železov oksid
Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy. 
Pri bolnikih, ki imajo raka dojk s pozitivnimi hormonskimi receptorji (HR), je morala bolezen prav tako napredovati med predhodnim hormonskim zdravljenjem ali po njem, ali morajo bolniki veljati za neprimerne za hormonsko zdravljenje.
The study compared the efficacy of olaparib maintenance treatment taken until progression with no maintenance treatment in 265 (136 olaparib and 129 placebo) PSR serous ovarian cancer patients who were in response (CR [complete response] or PR [partial response]) confirmed as per RECIST and/or as per CA-125 criteria as defined by Gynecologic Cancer InterGroup (GCIG) (at least a 50% reduction in CA-125 levels from the last pre-treatment sample, confirmed 28 days later) following completion of two or more previous platinum-containing chemotherapy. 
Študija je primerjala učinkovitost vzdrževalnega zdravljenja z olaparibom, uporabljanim do napredovanja, z neuporabo kakršnega koli vzdrževalnega zdravljenja pri 265 bolnicah (136 olaparib in 129 placebo) s PSR seroznim rakom jajčnikov, ki so bile v odzivu (popolnem odzivu [CR - complete response] ali delnem odzivu [PR - partial response]) potrjenem po merilih RECIST in/ali po kriterijih vrednosti CA-125, kot jih opredeljuje GCIG (Gynecologic Cancer InterGroup) (vsaj 50 % zmanjšanje koncentracije CA-125 od zadnje meritve na vzorcu pred zdravljenjem, potrjeno 28 dni pozneje), po dokončanju dveh ali več predhodnih kemoterapij na osnovi platine.
If a strong or moderate CYP3A inhibitor must be co-administered, the dose of Lynparza should be reduced (see sections 4.2 and 4.5). 
Če je treba sočasno uporabiti močen ali zmeren zaviralec CYP3A, je treba odmerek zdravila Lynparza zmanjšati (glejte poglavji 4.2 in 4.5).
Among the patients entering the trial with measurable disease (target lesions at baseline), an objective response rate of 41% was achieved in the Lynparza arm versus 17% on placebo. 
Med bolnicami, ki so vstopile v preizkušanje z merljivo boleznijo (ciljne lezije izhodiščno), je v skupini z zdravilom Lynparza doseglo objektivni delež odgovora 41 % bolnic in v skupini s placebom 17 % bolnic.
For patients with platinum sensitive relapsed high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer, it is recommended that treatment be continued until progression of the underlying disease or unacceptable toxicity. 
Pri bolnicah s ponovitvijo epitelijskega raka visokega gradusa z izvorom v jajčnikih, jajcevodih ali peritoneju, občutljivega na platino, je zdravljenje priporočljivo nadaljevati do napredovanja osnovne bolezni ali do nesprejemljive toksičnosti.
An exposure-response relationship between olaparib and decreases in haemoglobin has been demonstrated. 
Med olaparibom in znižanjem hemoglobina je bilo dokazano razmerje izpostavljenosti in odziva.
Do not take Lynparza if any of the above apply to you. 
Ne vzemite zdravila Lynparza, če navedeno velja za vas.
Lynparza co-administration with strong or moderate CYP3A inhibitors is not recommended (see section 4.5). 
Sočasna uporaba zdravila Lynparza z močnimi ali zmernimi zaviralci CYP3A ni priporočljiva (glejte poglavje 4.5).
It is used after the cancer has responded to previous treatment with standard platinum-based chemotherapy. 
Uporabljamo ga potem, ko se je rak odzval na predhodno zdravljenje s standardno kemoterapijo na osnovi platine.
Lynparza is a white, opaque, hard capsule, marked with “OLAPARIB 50 mg” and the AstraZeneca logo in black ink. 
Zdravilo Lynparza je bela, neprozorna trda kapsula z oznako "OLAPARIB 50 mg" in logom družbe AstraZeneca, natisnjenima s črnim črnilom.
Dose adjustments for co-administration with CYP3A inhibitors Concomitant use of strong or moderate CYP3A inhibitors is not recommended and alternative agents should be considered. 
Prilagoditve odmerka med sočasno uporabo zaviralcev CYP3A Sočasna uporaba močnih ali zmernih zaviralcev CYP3A ni priporočljiva in razmisliti je treba o drugih učinkovinah.
Patients whose disease had recurred >6 months after completion of penultimate platinum-based chemotherapy were enrolled. 
Vključene so bile bolnice, ki se jim je bolezen ponovila > 6 mesecev po dokončanju predzadnje kemoterapije na osnovi platine.
Nonclinical studies in rats have shown that olaparib causes adverse effects on embryofoetal survival and induces major foetal malformations at exposures below those expected at the recommended human dose of 400 mg twice daily. 
Predklinične študije na podganah so pokazale, da ima olaparib neželene učinke na embrio-fetalno preživetje ter povzroča pomembne malformacije ploda pri izpostavljenostih, manjših od pričakovanih pri priporočenem odmerku za človeka 400 mg dvakrat na dan.
No unexpected adverse reactions were reported in a small number of patients who took a daily dose of up to 900 mg of olaparib tablets over two days. 
Pri maloštevilnih bolnicah, ki so prejemale dnevni odmerek do 900 mg tablet olapariba v teku dveh dni, niso poročali o nepričakovanih neželenih učinkih.
In the olaparib arm 8% with measurable disease had a complete response versus 1.5% of patients in the comparator arm; 74/167 (44%) of patients in the olaparib arm had a partial response versus 14/66 (21%) of patients in the chemotherapy arm. 
Popoln odziv je doseglo 8 % bolnikov v skupini z olaparibom in merljivo boleznijo ter 1,5 % v skupini s primerjalnim zdravilom; delen odziv je doseglo 74/167 (44 %) bolnikov v skupini z olaparibom in 14/66 (21 %) v skupini s kemoterapijo.
Important differences in posology between Lynparza tablets and capsules Lynparza tablets (100 mg and 150 mg) should not be substituted for Lynparza capsules (50 mg) on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation. 
Pomembne razlike v odmerjanju med tabletami in kapsulami zdravila Lynparza Tablet zdravila Lynparza (100 mg in 150 mg) se ne sme zamenjati s kapsulami zdravila Lynparza (50 mg) na podlagi miligrama za miligram, ker se odmerjanje in biološka uporabnost med eno in drugo obliko razlikujejo.
In Study 19, the incidence of anaemia was 22.8% (CTCAE grade ≥3 7.4%) and the incidences of dose interruptions, reductions and discontinuations for anaemia were 2.9%, 5.1% and 0%, respectively; 16.2% of patients treated with olaparib needed one or more blood transfusions during the treatment. 
V Študiji 19 je bila pojavnost anemije 22,8 % (≥ 3. stopnje po CTCAE 7,4 %), pojavnost prekinitev uporabe 2,9 %, zmanjšanj odmerka 5,1 % in prenehanj uporabe 0 %; 16,2 % bolnic, ki so prejemale olaparib, je med zdravljenjem potrebovalo eno ali več transfuzij.